newsNoveCite has an exclusive licence to develop and commercialise mesenchymal…
8 October 2020 | By Hannah Balfour (European Pharmaceutical Review)
NoveCite has an exclusive licence to develop and commercialise mesenchymal stem cell therapies to treat acute respiratory conditions such as Acute Respiratory Distress Syndrome (ARDS).